M2R
0.003
50%
CNJ
0.02
-73.7%
RAD
0.026
44.4%
NAE
0.002
-33.3%
MEM
0.004
33.3%
SPX
0.002
-33.3%
VKA
0.009
28.6%
RKB
0.003
-25%
RDN
0.005
25%
TAR
0.018
-25%
DRO
2.83
23%
OEL
0.004
-20%
NFM
0.017
21.4%
TDO
0.14
-17.6%
4DX
2.95
20.9%
BMO
0.033
-15.4%
VAR
0.006
20%
AX8
0.006
-14.3%
PTX
0.11
18.3%
BNL
0.006
-14.3%
BLU
0.007
16.7%
ECS
0.006
-14.3%
GLL
0.007
16.7%
ENV
0.006
-14.3%
MGL
0.245
16.7%
SER
0.006
-14.3%
VSR
0.035
16.7%
AZY
0.537
-13.4%
EOS
7.44
15.2%
ALM
0.007
-12.5%
BKB
0.8
15.1%
MML
0.028
-12.5%
SNX
0.031
14.8%
PL9
0.007
-12.5%
HPG
1.385
14.5%
SRJ
0.014
-12.5%
CLX
2.15
13.2%
GG1
0.185
-11.9%
MQR
0.009
12.5%
D3E
0.305
-11.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Interviews

Epiminder (ASX:EPI) is a medical device company developing next-generation technology for continuous brain monitoring in epilepsy patients. The Company is advancing its DETECT study in the United States, a large-scale clinical trial designed to support future reimbursement for its Minder® device. Momentum is building, with 18 leading US medical centres now contracted and patient enrolment ramping quickly, positioning the study for significant expansion this year. Epiminder CEO Rohan Hoare joins Lel Smits from The Stock Network to discuss what this progress means, how the study is tracking against key milestones, and Epiminder's plans as it scales. 1. DETECT study momentum We’ve seen a strong ramp-up in the DETECT study, with 18 US medical centres now contracted and patient enrolment increasing. What’s driving this acceleration and how should investors interpret this progress? 2. Path to scale and key milestones You’re targeting 210 patients across up to 25 leading US sites. How important are the next few months in terms of hitting enrolment milestones? 3. Commercial pathway and funding position With a strong cash balance of $83.8 million and funding through to 2028, how does this position Epiminder to execute on DETECT, complete G1 development, and move towards commercial rollout? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Epiminder (ASX:EPI): DETECT study momentum accelerates, scaling towards US approval
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS44OEYxMzRDRDg1REM4QjIw

Epiminder (ASX:EPI): DETECT study momentum accelerates, scaling towards US approval

Tetratherix (ASX:TTX) is integrating regenerative medicine with advanced health AI, data science and digital infrastructure through its Tetramatrix™ platform. As multiple products progress through clinical validation and regulatory pathways, Tetratherix is also building a scalable AI-driven data platform to accelerate discovery, improve decision-making and support commercial growth. Vice President of Digital Science, Andrew (AJ) Fisher joined Tetratherix to lead its Digital Science pillar and is a senior technology leader with 25+ years’ experience across AI, data platforms, Internet of Things (IoT) and digital transformation. AJ. joins The Stock Network’s Lel Smits to discuss how artificial intelligence in healthcare and connected data systems are reshaping how Tetratherix is developing and scaling its products. 1. Building a health AI platform in regenerative medicine How is your background in AI, data science and digital strategy helping to build a health AI platform at Tetratherix, and in simple terms, how does this improve how new medical treatments are discovered and developed? 2. Connecting data across lab, manufacturing and real-world healthcare You’re designing a connected healthcare data ecosystem that links experiments, production and external data. How does this kind of end-to-end data integration in healthcare help accelerate product development and enable scalable commercialisation? 3. Creating a compounding AI-driven data advantage You’ve spoken about building a compounding data asset powered by AI. How does this approach to machine learning in healthcare create a long-term competitive advantage and position Tetratherix as a scalable digital health platform? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Tetratherix (ASX:TTX): The tools to leverage health AI & data to scale regenerative medicine
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5EMzdGRjBBQzVCNEY2NDhG

Tetratherix (ASX:TTX): The tools to leverage health AI & data to scale regenerative medicine

Tetratherix (ASX:TTX) latest quarterly results has been marked by progress across commercial agreements, clinical programs and manufacturing scale-up, alongside a disciplined financial position. The quarter highlighted the Company’s transition toward revenue generation, underpinned by a landmark agreement with Superpower and continued advancement across its core product portfolio. Chief Financial Officer, Cherie Beach, is responsible for overseeing Tetratherix’s financial strategy and ensuring the business is well-positioned to execute on its next phase of growth. Cherie joins The Stock Network’s Lel Smits to discuss the key takeaways from the latest quarterly results and priorities heading into the next phase of development and commercialisation. 1. Key takeaways from Q3 FY26 results Q3 FY26 included major milestones across revenue, clinical progress and commercial readiness. From your perspective, what were the most important outcomes from the quarter? 2. Building momentum into near-term catalysts With the Superpower agreement, progression of Tutelix into pivotal trials, and continued advancement of TetraDerm and Tegenix, what are the key milestones investors should be watching over the next 6-12 months? 3. Balancing investment with execution With a strong cash position and continued investment into R&D and manufacturing, what is Tetratherix prioritising to ensure you execute on upcoming milestones while maintaining financial discipline? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Tetratherix (ASX:TTX): Executing on commercialisation & scaling revenue
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS44QUE0MzNDRkM4RjA0Njcy

Tetratherix (ASX:TTX): Executing on commercialisation & scaling revenue

Starpharma (ASX:SPL, US OTC:SPHRY) is an innovative biotechnology company advancing dendrimer technology from the lab to the patient. The company has recently achieved an important regulatory milestone, receiving positive feedback from the US FDA on the clinical development strategy and Phase 1 first-in-human study design for its DEP® HER2 radiotherapy program. Starpharma Chief Executive Officer, Cheryl Maley, joins Lel Smits from The Stock Network to discuss the transition from preclinical to clinical development and what comes next from here. 1. FDA milestone: DEP® HER2 first-in-human pathway Starpharma has just received FDA alignment on the DEP® HER2 first-in-human Phase 1 study design and overall clinical strategy. What is the significance of this announcement? 2. Clinical pathway and platform validation With FDA confirmation of a clear development pathway in a high unmet-need setting, DEP® HER2 highlights the potential of Starpharma’s dendrimer platform in targeted radiopharmaceuticals. What comes next from here? 3. Upcoming catalysts DEP® HER2 is on track to enter Phase 1 in H2 CY2026, with regulatory and site preparation underway and a pathway to future US development. What upcoming catalysts should investor be watching out for? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Starpharma (ASX:SPL, US OTC:SPHRY:SPL): FDA validates path to DEP® HER2 first-in-human study
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4zOTVGMDIwNzkzODk2QTQ1

Starpharma (ASX:SPL, US OTC:SPHRY:SPL): FDA validates path to DEP® HER2 first-in-human study

Schoolblazer Limited (ASX:SBZ), formerly Hancock & Gore Limited is undergoing a strategic transformation, pivoting toward its wholly owned Schoolblazer Group, a technology-enabled, global schoolwear and sportswear platform. Led by Executive Chairman Tim James, co-founder of Schoolblazer UK, the business is targeting significant international growth, supported by strong e-commerce capability, long-term school contracts and expanding exposure to private education markets. Tim James joins The Stock Network's Lel Smits to discuss how Schoolblazer is positioning itself to capitalise on structural growth in global private education and changing consumer expectations. 1. Strategic repositioning under Schoolblazer Hancock & Gore is transitioning to become Schoolblazer Limited, reflecting a clear focus on its schoolwear operations. What does this shift mean strategically for the business, and how does it reshape your long-term growth priorities? 2. Scaling a global e-commerce model Schoolblazer’s direct-to-parent e-commerce platform is central to its offering, with high service levels and operational efficiency. What makes this model so scalable across regions, and how do you maintain consistency in customer experience as you expand internationally? 3. Building defensibility through contracts and capability The business benefits from long-term school contracts and high barriers to entry driven by technology and operational expertise. How important are these factors in underpinning recurring revenue and protecting market share as competition evolves? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Schoolblazer (ASX: SBZ): Repositioning to scale a global schoolwear platform
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS43OTQxRDdENkQwNEZGMkQy

Schoolblazer (ASX: SBZ): Repositioning to scale a global schoolwear platform

4DMedical (ASX:4DX), a global leader in respiratory imaging technology, has delivered a transformational period, with the stock rising more than 2000%, underpinned by rapid clinical adoption, regulatory milestones and strong institutional support. Most recently, 4DMedical announced the deployment of CT:VQ™ at Mayo Clinic, the number one ranked hospital in the United States, marking one of the most significant institutional endorsements to date. This follows adoption across five other leading U.S. Academic Medical Centers, highlighting extraordinary commercial momentum since FDA clearance in September 2025. Further strengthening its global position, 4DMedical secured CE Mark certification for CT:VQ™, enabling commercial rollout across Europe, alongside completing an $83 million placement to fund expansion and accelerate growth. Ahead of presenting at TIP Group’s Emerging Wealth Winners conference, Founder, CEO and CTO, Dr Andreas Fouras joins The Stock Network’s Lel Smits to discuss 4DMedical's global expansion strategy and pathway to establishing CT:VQ™ as a new standard of care globally. 1. Transformational momentum and global validation 4DMedical has delivered a remarkable run with CT:VQ™ now deployed across six leading U.S. Academic Medical Centers, including the Mayo Clinic most recently. What does it signal about the technology’s potential to become a new standard of care and what's next from here? 2. Europe expansion and capital strategy With CE Mark certification secured and an $83 million placement just completed to fund European expansion, 4DMedical is now positioned across two major healthcare markets. How are you approaching the rollout into Europe? 3. Commercial inflection and scaling economics The focus will now naturally shift to commercialisation and revenue scale. Can you walk us through the key inflection points over the next 12 months, particularly around converting pilot deployments, like Mayo Clinic, into full commercial contracts, expanding within existing hospital networks and driving reimbursement adoption? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
4DMedical (ASX:4DX): Outlines plans to accelerate rapid U.S. adoption and rollout into Europe
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5FOTM0MjQ2Q0ZDQURDRUFE

4DMedical (ASX:4DX): Outlines plans to accelerate rapid U.S. adoption and rollout into Europe

Tasmea (ASX:TEA), a diversified provider of essential trade services to blue-chip asset owners across Australia, has delivered a strong first half (H1 FY26) result, highlighted by record revenue, solid earnings growth and continued balance sheet strength. The result was driven by organic growth across key segments, contributions from recent acquisitions, and strong demand across mining, infrastructure and electrification sectors, alongside disciplined capital management and high cash conversion. Ahead of presenting at TIP Group’s Emerging Wealth Winners conference, Managing Director of Tasmea Stephen Young joins The Stock Network’s Lel Smits to discuss its growth strategy, integration of WorkPac and outlook for FY26. 1. Record growth and earnings momentum Tasmea has delivered standout first half growth, with revenue up more than 60% and strong increases in EBIT and NPAT, alongside excellent cash conversion. What were the key drivers behind this performance, and how sustainable is this level of growth into the second half and beyond? 2. Strategy, acquisitions and outlook With the successful acquisition and integration of WorkPac, a strong pipeline of programmatic acquisitions, and record secured revenue for the second half, Tasmea appears well positioned. How are you thinking about balancing organic growth with acquisitions, and what are your key priorities as you execute on your FY26 guidance? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Tasmea (ASX:TEA): Scaling through acquisitions, workforce expansion & essential services demand
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5BMDNGMkVEMjBGMzNGNEJC

Tasmea (ASX:TEA): Scaling through acquisitions, workforce expansion & essential services demand

Pengana Private Equity Trust (ASX:PE1) provides investors access to high-quality global private companies through a single listed vehicle on the Australian Securities Exchange. The portfolio spans private equity, private credit and opportunistic investments across sectors and geographies. Joining The Stock Network’s Lel Smits, Pengana Capital Group Executive Director Adam Myers discusses recent portfolio performance, the impact of major holdings including SpaceX, and how the Trust continues to unlock value from leading private companies globally. 1. Portfolio performance and recent developments The Pengana Private Equity Trust recently delivered positive monthly returns with strong contributions from its investment in SpaceX which is a very significant holding in the portfolio. What is the current exposure to SpaceX within PE1 and what are the latest developments with this company? 2. Private market opportunity and portfolio relevance How does the growth of companies like SpaceX demonstrate the opportunity set available through private markets and the importance of incorporating private markets into investment portfolios? 3. Spotlight on a lesser-known portfolio company The portfolio spans industries from financial services and healthcare technology to exchanges and mobility platforms – many of which we wouldn’t have heard of. What is one of the lesser known names you’re most excited by and why? 4. Impact of geopolitical uncertainty on private equity Uncertainty has increased following the recent conflict and the flow through to energy markets. It is still early, but are you seeing any impact on private equity activity? None of Pengana Private Equity Trust (“PE1”), Pengana Investment Management Limited (ABN 69 063 081 612, AFSL 219 462) (“Responsible Entity”), Grosvenor Capital Management, L.P., nor any of their related entities guarantees the repayment of capital or any particular rate of return from PE1. Past performance is not a reliable indicator of future performance, the value of investments can go up and down. This document has been prepared by the Responsible Entity and does not take into account a reader’s investment objectives, particular needs or financial situation. It is general information only and should not be considered investment advice and should not be relied on as an investment recommendation. Pengana Investment Management Limited (Pengana) (ABN 69 063 081 612, AFSL 219 462) is the issuer of units in the Pengana Private Equity Trust (ARSN 630 923 643) (the Trust). Before acting on any information contained within this report a person should consider the appropriateness of the information, having regard to their objectives, financial situation and needs. An investment in the Trust is subject to investment risk including a possible delay in repayment and loss of income and principal invested. _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Pengana Private Equity Trust (ASX:PE1): Strong portfolio momentum as SpaceX doubles in value
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5BNTZDRUVBRkUwRDU3N0FF

Pengana Private Equity Trust (ASX:PE1): Strong portfolio momentum as SpaceX doubles in value

EQ Resources (ASX:EQR) share price is up almost 900% in the last six months. The company is a high-grade tungsten producer, operating two of the largest tungsten projects globally outside of China, Mt Carbine in Queensland and Barruecopardo in Spain and playing a critical role in supplying a diversified, Western source of tungsten, a mineral essential for industrial applications, advanced manufacturing, and global defence. Ahead of appearing at the Sydney Mining Club, Managing Director Craig Bradshaw joins Lel Smits from The Stock Network to discuss how EQ Resources is positioning itself as a key player in the global push to secure critical mineral supply chains amid tightening Chinese export controls and record tungsten prices. 1. The strategic importance of tungsten Tungsten is increasingly being recognised as a critical mineral, particularly given its importance in defence and high-performance industrial applications. Why is tungsten is so strategically important and how is EQ Resources is contributing to Western supply security? 2. Scale and growth across global assets EQ Resources has built a significant resource base across Mt Carbine in Australia and Barruecopardo in Spain. How do these assets underpin your growth strategy and long-term production outlook? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
EQ Resources (ASX:EQR) Powering Western tungsten supply surge to meet critical mineral demand
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS44QjI0MDE3MzFCMUVBQTkx

EQ Resources (ASX:EQR) Powering Western tungsten supply surge to meet critical mineral demand

View More

Get the latest ASX stock market news delivered to your inbox

By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy